September 13, 20231, 3, administration, agency, analysis, analytics, Biden, business, Business Analysis, cbd, compliance, controlled substances act, dea, Department of Health and Human Services, Federal, government, HHS, I, III, industry, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, reclassify, recommend, recommendation, recreational, regulation, regulations, regulatory, schedule, state

HHS Recommends Rescheduling Cannabis, Surprising an Entire Industry

In the most unexpected development to hit the cannabis industry in years, the U.S. Department of Health and Human Services’ (HHS) Secretary […]

August 31, 20231, 3, administration, analysis, analytics, Biden, business, Business Analysis, cannabis, dea, Federal, government, HHS, I, III, law, legal, legalization, legalize, legislation, marijuana, market, medical, medicine, recreational, regulation, regulatory, rescheduling, schedule, scheduling, state

HHS Recommends DEA Reschedule Cannabis to Schedule III

Massively promising news for the cannabis industry today that many are calling historic: the Department of Health and Human Services (HHS) has […]

November 10, 2022280E, analysis, analytics, bank, banking, business, Business Analysis, cannabis, Canopy, capital, CEO, colorado, company, compliance, Corporation, credit union, cultivation, debt, dispensary, extraction, Federal, finance, financial, financing, government, growing, growth, illicit, industry, Interest, international, law, legal, legality, legalization, legalize, legislation, lending, license, marijuana, market, medical, medicine, parties, Partner Colorado Credit Union, party, PCCU, premium, president, product, program, Quality, rate, recreational, regulation, regulations, regulatory, retail, Safe Harbor, safety, schedule, state, strategy, Sundie Seefried, thc, third, underwriting

A Q&A with Sundie Seefried, President & CEO of Safe Harbor Financial

As the former CEO of Partner Colorado Credit Union (PCCU), Sundie Seefried has been in the credit union space for 39 years. […]

May 5, 2022Act, AML, analysis, analytics, bank, banking, BSA, business, Business Analysis, cannabis, cbd, CDD, civil, compliance, consumer, CRB, criminal, CSA, due diligence, EDD, Federal, finance, financial, government, growing, industry, lab, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, money, MORE, NBFI, penalties, product, recreational, regulation, regulations, regulatory, retail, risk, safe, schedule, transaction

Cannabis Banking: The Ins, the Outs & the Unknowns

As the legal cannabis market expands, banks and nonbank financial institutions (NBFIs) across the United States continue to explore how to safely […]

August 26, 20211, Act, ADOR, ALTA, analysis, analytics, bank, banking, blockchain, BSA, business, Business Analysis, cannabis, cash, compliance, compliant, CRB, crypto, CSA, Dama, digital, DOJ, economic, economy, Federal, finance, financial, government, growing, industry, institution, laundering, law, legal, legalization, legalize, legislation, lending, license, loan, marijuana, market, MLCA, money, NaturePay, Partners Credit Union, product, recreational, regulation, regulations, regulatory, retail, risk, Safe Harbor, Safe Harbor Private Banking, schedule, state, trend

Current Trends in Banking for Cannabis-Related Businesses

Cannabis is still federally illegal and is included on Schedule 1 of the Controlled Substances Act (CSA), along with such other substances […]

July 15, 2021analysis, bill, business, cannabis, Chuck Schumer, Congress, controlled substances, Controlled Substances Ac, Cory Booker, deschedule, draft, Federal, government, industry, law, leader, legal, legalization, legalize, legislation, license, list, majority, marijuana, market, recreational, regulation, regulatory, remove, Ron Wyden, schedule, senator, state

Senators Introduce The Cannabis Administration And Opportunity Act

During a press conference held today, Senate Majority Leader Chuck Schumer, Senate Finance Committee Chair Ron Wyden and Senator Cory Booker introduced […]

December 17, 20201, 19, 2020, 2021, 4, adult use, analysis, analytics, ballot, Biden, business, Business Analysis, CANADA, canadian, cannabis, cbd, commission, compliance, consumer, Coronavirus, court, COVID, COVID-19, cultivation, Denmark, deschedule, EC, economy, election, EU, Euro, europe, European, export, extraction, Federal, German, Germany, global, globe, government, growing, Holland, I, import, industry, initative, international, IV, law, legal, legalization, legalize, legislation, license, Luxembourg, marijuana, market, measure, medical, medicine, pandemic, policies, policy, Portugal, product, Quality, Recommendations, recreational, referendum, regulation, regulations, regulatory, reschedule, rescheduled, retail, safety, schedule, scheduling, spain, state, test, Testing, thc, UN, union, United Nations, vote, WHO, world, World Health Organization, worldwide

The 2020 Global Cannabis Regulatory Roundup

As a strange year heads to a final, painful finish, there have been some major (and some less so) changes afoot in […]

October 28, 20201, analysis, analytics, and Cosmetics Act, application, approval, approve, business, Business Analysis, cannabidiol, cannabis, cbd, clinical, clinical trials, compliance, consumer packaged goods, CPG, CSA, dea, derived, deschedule, descheduled, Dravet syndrome, drug, Drug Enforcement Administration, Epidiolex, epilepsy, extraction, FDA, FDCA, Federal, Federal Food, FFDCA, food and drug administration, formulation, government, GW, GW Pharma, hemp, industry, law, legal, legalization, legalize, legislation, Lennox-Gastaut syndrome, license, marijuana, market, medical, medicine, New, patent, pathway, patient, pharma, pharmaceutical, product, Product Development, program, regulation, regulations, regulatory, REMS, safety, schedule, seizures, state, Substances, thc, trial, TSC

How GW Pharma Won CBD

As of this writing, the United States Food and Drug Administration (FDA) has approved GW Pharma’s CBD drug Epidiolex for treating profound […]

September 24, 2020%, 0.3, 2018, analysis, analytics, business, Business Analysis, cannabidiol, cannabis, cbd, compliance, Concentrates & Extracts, consumer, controlled, cultivation, dea, derived, Drug Enforcement Administration, Edibles & Processing, extraction, farm bill, Federal, final, government, growing, hemp, industry, interim, justice department, lab, laboratories, laboratory, labs, law, legal, legalization, legalize, legislation, license, limit, marihuana, marijuana, market, product, Product Development, Quality, regulation, regulations, regulatory, rule, rulemaking, schedule, state, substance, test, Testing, thc

The DEA’s Interim Final Rule and its Impact on the Industrial Hemp Industry

On August 20, 2020, the Drug Enforcement Administration (DEA) published an Interim Final Rule on industrial hemp and hemp derivatives (the interim […]

September 10, 2020analysis, analytics, business, Business Analysis, cannabidiol, cannabis, cbd, compliance, Congress, congressional, controlled substances act, cultivation, dea, department of justice, derived, DOJ, Drug Enforcement Administration, farm, Farming, FDA, FDCA, Federal, food and drug administration, government, growing, hemp, industry, interim, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, National Institute of Standards and Technology, NIST, plant, plants, political, politics, product, Quality, recreational, reg, regulation, regulations, regulatory, retail, rule, safety, schedule, state, test, Testing, thc, THCA

CBD Industry Caught Between Regulators & Law Enforcement

The consumer-facing CBD industry operates in a regulatory gray zone even as it grows in prominence. Illegal to market as an unapproved […]